Why did you participate in the Biomapas Academy?
Everything started when I had a trip to a career fair during my studies. This was the first time I met Biomapas in person as there were several lecturers that presented the company itself and its activities. I remember thinking that I would like to work with this team as it piqued my interest.
Later, when I was working on my master’s degree, I came across an advertisement on social media for the Biomapas Academy. I already knew that I wanted to learn more about the pharma industry and was interested in various opportunities, so I applied for this opportunity.
How was your experience during the three months?
The Academy was a continuous cycle spanning several months of interesting lectures from true professionals with extensive knowledge. During this short time, I learned a lot about product development, research, safety information and its systems, different possible roles and their responsibilities, and new opportunities where young specialists can grow and find their place in the life sciences industry.
What did the future hold for you after the Academy?
A while after the Academy, I officially became part of Biomapas and its big family! With my background being an MPharm, I was always interested in drug safety. Therefore, I am working in the Pharmacovigilance Department as a Pharmacovigilance Project Management Assistant. I must say there are many interesting things to learn and experience that I am looking forward to with my team.
What would you say to the future participants?
If you are thinking about participating in the Academy, do not hesitate. Being an alumnus, I can say that you will definitely see the pharma industry from within. It will broaden your understanding; you will gain needed knowledge and experience in life sciences and will be able to apply that information working in your chosen field. I hope to see you at Biomapas!
Biomapas Academy
What is Clinical Research? Regulatory Affairs? Pharmacovigilance?
Running Pan‑European Multi‑Regional Trials with Flexible FSP Models
Discover how flexible FSP models help sponsors run multi-country clinical trials across Europe with greater control, speed, and regional alignment.
Choosing the Right QPPV Partner for EU and Global Compliance
Explore the essential functions of a QPPV and discover how to choose the right partner for pharmacovigilance.
How to achieve Multi-Region Pharmacovigilance Compliance: Critical Lessons from CIS and MENA
Explore the challenges of multi-region pharmacovigilance and learn strategies for compliance in CIS and MENA markets.
Enhancing Patient Recruitment in Niche Markets Through Clinical Trial Outsourcing
Explore clinical trial outsourcing and its role in overcoming recruitment challenges in clinical research for small biotech companies.
The use of AI/Automation in Pharmacovigilance: Ensuring Safety through Robust Processes
Discover how AI and automation are transforming pharmacovigilance, including Veeva’s signal management solutions, the role of NLP and machine learning in safety workflows, and future trends in AI.
Signal Detection: An Integrated Approach to Pharmacovigilance & Regulatory Compliance
Discover how efficient signal detection manages safety risks, ensuring compliance with global regulations.
Global Literature Review: Ensuring Safety through Robust Processes
Learn how our end-to-end GLR process enhances patient safety and supports regulatory compliance worldwide.
Site Startup Services in Clinical Trials: Leveraging Local Expertise
Learn how integrating site startup services within a flexible FSP model accelerates activation in CIS and CEE, reduces contract cycles, and improves predictability from first submission to first patient in.
Pharmacovigilance outsourcing for boosting compliance and safety for biotech companies
Explore why pharmacovigilance outsourcing is essential for biotech companies in 2025 to ensure compliance and patient safety.
Local Affiliate Services That Deliver the Best Results
Find out how local affiliate services can reduce compliance risks and support effective regulatory strategies in the pharma industry.
